or Try an Advanced Search...

    Technical Analysis for IMTX - Immatics N.V.

    Grade Last Price % Change Price Change
    B 12.00 3.27% 0.38
    IMTX closed up 3.27 percent on Monday, July 1, 2024, on 81 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical IMTX trend table...
    Date Alert Name Type % Chg
    Bullish Engulfing Bullish 0.00%
    Inside Day Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Support Bullish 3.27%
    Stochastic Buy Signal Bullish 3.27%
    Outside Day Range Expansion 3.27%
    Down 3 Days in a Row Weakness 3.27%
    Down 4 Days in a Row Weakness 3.27%
    Down 5 Days in a Row Weakness 3.27%
    Oversold Stochastic Weakness 3.27%
    Older End-of-Day Signals for IMTX ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 6 hours ago
    10 DMA Resistance about 7 hours ago
    Up 5% about 7 hours ago
    Up 1 ATR about 7 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    IMTX Chart by TradingView
    Basic chart:

    Profile

    Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immune System Immunotherapy Cancer Treatment Treatment Of Cancer Cell Therapy Virotherapy Immunotherapies T Cell Adoptive Cell Transfer

    Is IMTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 14 Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns
    May 21 Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation
    May 14 Immatics reports Q1 results
    May 14 Immatics Announces First Quarter 2024 Financial Results and Business Update
    Apr 29 Immatics N.V.: An Intriguing Developmental Concern
    Apr 27 Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
    Mar 21 Immatics reports FY results
    Mar 21 Immatics Announces Full Year 2023 Financial Results and Corporate Update
    Mar 15 With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
    Feb 3 Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
    See more IMTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.77
    52 Week Low 7.1583
    Average Volume 556,726
    200-Day Moving Average 10.77
    50-Day Moving Average 11.46
    20-Day Moving Average 12.58
    10-Day Moving Average 12.18
    Average True Range 0.59
    RSI (14) 48.98
    ADX 20.45
    +DI 16.46
    -DI 21.38
    Chandelier Exit (Long, 3 ATRs) 12.01
    Chandelier Exit (Short, 3 ATRs) 12.57
    Upper Bollinger Bands 13.72
    Lower Bollinger Band 11.44
    Percent B (%b) 0.24
    BandWidth 18.12
    MACD Line 0.07
    MACD Signal Line 0.25
    MACD Histogram -0.1822
    Fundamentals Value
    Market Cap 1.24 Billion
    Num Shares 103 Million
    EPS -1.22
    Price-to-Earnings (P/E) Ratio -9.84
    Price-to-Sales 15.41
    Price-to-Book 4.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.99
    Resistance 3 (R3) 12.95 12.58 12.83
    Resistance 2 (R2) 12.58 12.33 12.60 12.77
    Resistance 1 (R1) 12.29 12.17 12.44 12.33 12.71
    Pivot Point 11.92 11.92 11.99 11.94 11.92
    Support 1 (S1) 11.63 11.67 11.78 11.67 11.29
    Support 2 (S2) 11.26 11.51 11.28 11.23
    Support 3 (S3) 10.97 11.26 11.18
    Support 4 (S4) 11.01